Ascletis Pharma of Hangzhou led a second tranche of a Series E financing fpr the Bay Area’s Sagimet that brings the financing to $25 million. Ascletis, which also led the first tranche, acquired China rights to Sagimet’s novel non-alcoholic steatohepatitis (NASH) candidate as part of the deal. In April 2019, Sagimet dosed the first patient in a US-China Phase II trial of the FASN (fatty acid synthase) inhibitor, TVB-2640. Ascletis focuses on viral, cancer and fatty liver diseases with two treatments for hepatitis C approved in China. Source: China Biotoday
